Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

519
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
519
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

59
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
59
Cancer Survival Analysis01:21

Cancer Survival Analysis

811
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
811
Statistical Methods for Analyzing Epidemiological Data01:25

Statistical Methods for Analyzing Epidemiological Data

1.1K
Epidemiological data primarily involves information on specific populations' occurrence, distribution, and determinants of health and diseases. This data is crucial for understanding disease patterns and impacts, aiding public health decision-making and disease prevention strategies. The analysis of epidemiological data employs various statistical methods to interpret health-related data effectively. Here are some commonly used methods:
1.1K
Hazard Ratio01:12

Hazard Ratio

686
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
686
Drug Regulation01:25

Drug Regulation

3.2K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
3.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sacituzumab tirumotecan in participants with advanced or metastatic urothelial carcinoma and disease progression after chemotherapy and immune checkpoint inhibitors.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Expediting treatments in the 21st century: orphan drugs and accelerated approvals.

Orphanet journal of rare diseases·2024
Same author

MIT CAACB Risk Assessment Case Study: Assessing Virus Cross-Contamination Risk between Two Simultaneous Processes in an Open Biomanufacturing Facility.

PDA journal of pharmaceutical science and technology·2022
Same author

TROG 14.04: Multicentre Study of Feasibility and Impact on Anxiety of DIBH in Breast Cancer Patients.

Clinical oncology (Royal College of Radiologists (Great Britain))·2022
Same author

External control arms in oncology: current use and future directions.

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

Corrigendum to "Bringing safe and effective therapies to premenopausal women with breast cancer: efforts to broaden eligibility criteria": [Annals of Oncology 32 (2021) 950-953].

Annals of oncology : official journal of the European Society for Medical Oncology·2022

Related Experiment Video

Updated: Mar 15, 2026

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.8K

A Benefit-Risk Analysis Approach to Capture Regulatory Decision-Making: Non-Small Cell Lung Cancer.

G K Raju1, K Gurumurthi1, R Domike1

  • 1Light Pharma, Inc., Cambridge, Massachusetts, USA.

Clinical Pharmacology and Therapeutics
|September 13, 2016
PubMed
Summary
This summary is machine-generated.

This study applied quantitative benefit-risk analysis to 20 US Food and Drug Administration (FDA) decisions for advanced non-small cell lung cancer (NSCLC) drugs. Findings show FDA approval decisions align with this quantitative benefit-risk logic.

More Related Videos

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model
07:13

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Published on: April 18, 2025

842
An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.7K

Related Experiment Videos

Last Updated: Mar 15, 2026

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.8K
Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model
07:13

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Published on: April 18, 2025

842
An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.7K

Area of Science:

  • Oncology
  • Pharmacovigilance
  • Regulatory Science

Background:

  • Drug regulatory agencies globally rely on qualitative benefit-risk assessments for drug approval.
  • Quantifying these benefit-risk analyses is of significant interest to improve regulatory processes.
  • Advanced non-small cell lung cancer (NSCLC) presents a critical area for evaluating new therapeutic approvals.

Purpose of the Study:

  • To apply a quantitative benefit-risk analysis framework to regulatory decision-making for new NSCLC drugs.
  • To analyze the consistency of US Food and Drug Administration (FDA) approval outcomes with quantitative benefit-risk logic.
  • To explore the use of overall survival (OS), overall response rate (ORR), and progression-free survival (PFS) in benefit assessment.

Main Methods:

  • A quantitative benefit-risk analysis was performed on 20 FDA decisions for advanced NSCLC treatments (2003-2015).
  • Benefits were assessed using median overall survival (OS) or estimated OS from overall response rate (ORR) or progression-free survival (PFS).
  • Risks were evaluated based on the magnitude of harm and its likelihood of occurrence, including a sensitivity analysis for uncertainty.

Main Results:

  • The analysis demonstrated that FDA approval decisions for advanced NSCLC drugs were consistent with the applied quantitative benefit-risk logic.
  • Benefit assessment utilized available OS data, with estimations from ORR and PFS used when direct OS data was absent.
  • Risk evaluation incorporated both the severity and probability of adverse events, with sensitivity analysis addressing uncertainty.

Conclusions:

  • Quantitative benefit-risk analysis provides a logical framework that aligns with FDA approval decisions for advanced NSCLC therapies.
  • This approach offers a structured method for evaluating new drug candidates, enhancing transparency in regulatory processes.
  • Further application of quantitative methods can support more consistent and objective drug approval evaluations.